De la molécula a la matrix: una opción para el manejo del dolor moderado a severo

De la molécula a la matrix: una opción para el manejo del dolor moderado a severo. From Molecule to Matrix: An Option for the Management of Moderate to Severe Chronic Pain Joseph V. Pergolizzi Jr, Robert B Raffa. Pain Medicine News 2011;9:08 Butrans (buprenorphine) Transdermal System CIII is the first FDA-approved transdermal formulation of buprenorphine indicated for the management of moderate to severe chronic pain in patients who require a continuous, around-the-clock opioid analgesic for an extended period of time. http://www.painmedicinenews.com/download/SR1143_WM.pdf

Atentamente Anestesiología y Medicina del Dolor www.anestesia-dolor.org